# PMDA's activity against COVID-19

Kenichi Mikami Office Director Office of Review Management PMDA

# PMDA's Safety Triangle

#### **Product Reviews**



- Improving quality of services by promoting regulatory science
- Promoting globalization
- Developing the governance/compliance system based on organizational role and social position

## PMDA's Efforts to Combat COVID-19

## https://www.pmda.go.jp/english/about-pmda/0002.html

About PMDA	۰	Find Re	view reports,	, PI			Favorite page		Contact us
Menu for each of you Our recommended conte Menu of each produce	ents		Regulatory norities		Healthcare essionals	۲ ک	or Academia		for Business
Home	Re	views	Post-ma Safety M		Relief Ser for Adve Health Eff	rse	Regulatory Science Standard Development(JF		International Activities
				Add this p	age to "Favori	te page	" 🔒 Print	the te	xt日本語 ページはる

Home > About PMDA > Announcements > PMDA's Efforts to Combat COVID-19

#### 

#### PMDA's Efforts to Combat COVID-19

PMDA's Efforts to Combat COVID-19

#### Statement by the Chief Executive Dr. FUJIWARA

lssue #	Title	Date
9	Special Approval for Emergency on First COVID-19 Vaccine in Japan 🕿	February 16, 2021
8	PMDA Reveals Principles on Evaluation of COVID-19 Vaccines	October 12, 2020
7	PMDA to Offer Free Scientific Advice for COVID-19 Vaccines Development	October 6, 2020
6	For Your Access to Japanese Clinical Trial/Clinical Research Information	June 4, 2020
5	First Approval of Antigen Test for COVID-19	May 13, 2020
4	Special Approval for Emergency on Remdesivir for COVID-19	May 8, 2020
3	Four IVDs Approvals for COVID-19 and Response to the Increased	April 21, 2020
2	PMDA Takes Further Steps to Speed up Clinical Development of COVID- <u>19 Products</u>	April 10, 2020
1	PMDA pledge to tackle COVID-19 Pandemic 🐀	March 31, 2020

## Actions against COVID-19

March 2020  $\sim$ 

-Statements by PMDA Chief Executive Dr. Fujiwara-



- Special Approval for Emergency on First COVID-19 Vaccine in Japan
- PMDA Reveals Principles on Evaluation of COVID-19 Vaccines
  - PMDA to Offer Free Scientific Advice for COVID-19 Vaccines Development
  - For your Access to Japanese Clinical Trial/Clinical Research Information
  - First Approval of Antigen Test for COVID-19
  - Special Approval for Emergency on Remdesivir for COVID-19
  - Four IVDs Approvals for COVID -19 and Response to the Increased Ventilator Demand
  - PMDA Takes Further Steps to Speed up Clinical Development of COVID-19 Products
- PMDA pledge to tackle COVID-19 Pandemic
  - (As of May25, 2021) 4

6th October, 2020 Ensuring access to vaccines against the SARS-CoV-2 (novel coronavirus) is the most pressing cha Pharmaceuticals and Medical Devices Agency (PMDA) cases reaching 独立行政法人 医薬品医療機器総合機構 actions to ad First Approval of Antigen Test for COVID-19 13th May, 2020 Pharmaceuticals and Medical Devices Agency (PMDA COVID-使立行政法人 医蓼品医檀機器総合機構 product ssion and ne regular Special Approval for Emergency liagnostic on Remdesivir for COVID-19 9 in Japan 8th May, 2020

Pharmaceuticals and Medical Devices Agency (PMDA)

PMDA to Offer Free Scientific Advice

for COVID-19 Vaccines Development

独立行政法人 医藜品医療機器総合機構

The MHLW granted the Special Approval for Emergency for treatment of COVID-19 on  $7^{th}$  May, 2020 with approval conditions to allow the access to the potential treatment of this disease.

What is Special Approval for Emergency?

Under article 14-3 of the Pharmaceuticals and Medical Devices Act, a certain medical product may be approved when 1) an emergency situation requires an unapproved medical product to be used to prevent damage to the public health caused by the spread of diseases, 2) such emergency situation cannot be managed appropriately

Other Actions against COVID-19 For COVID-19 Products

- Drug approval for COVID-19
- IVDs approval for COVID-19
- Close interaction with sponsors, global regulators and WHO
- Allowing quick start of clinical

## **For non-COVID-19 Products**

 Providing information on how to manage clinical trials

## Allowing Quick Start of Clinical Trials



URL: https://www.pmda.go.jp/english/int-activities/0001.pdf

# Q&A on Management of Clinical trials during COVID-19 Pandemic

Provides alternative measures that can be taken by the sponsor and/or clinical trial site when the process predetermined in the study protocol is not deemed feasible due to the COVID-19 situation.

\_\_\_\_\_

新型コロナウイルス感染症の影響下での医薬品、医療機器及び再生医療等製品の 治験実施に係るQ&Aについて

現在実施中の医薬品、医療機器及び再生医療等製品の治験において、新型コロナウイルス感染症 の影響により治験実施計画書の規定及び通常の手順と異なる対応を取らざるを得ない場合は、被 膝者の安全確保を最優先とした上で、経緯及び対応の記録を残し、その妥当性について説明できる ようにしてください。また、実施医療機関において疑義が生じる場合の対応については、まずは治 験依頼者と協議・相談してください。

これまでにいただいたお問い合わせに対する回答を、以下にご紹介しますので参考としてくださ い。なお、内容については、今後のお問い合わせに応じて更新いたします。

> 2020年3月27日作成 2020年4月2日更新 2020年4月21日更新

March 2020  $\sim$ 

Q1 実施医療機関に未院できない等により、統築者が治験薬、治験機器又は治験製品(以下「治 験実等」という。)を直接受け取れない場合、実施医療機関から被験者宅に配送してよい か。(実施医療機関・治験佐頼者)

実施医療機関と医薬品GCP省令第39条の2、医療機器GCP省令第59条又は再生 医療等製品GCP省令第59条に基づく委受託契約を締結した配送業者、<u>または、実施医 療機関の治験協力者</u>により、実施医療機関から被験者宅に治験薬等を配送することは可 能である。その際、試験デザイン、治験薬等の性質、被験者の状態等を考慮の上、<u>同意を</u> <u>得た被験者において</u>実施医療機関の責任のもと実施すること。なお、運搬中の治験薬等の 品質管理に加え、被験者への交付を確実に行うための手順を予め定めておくこと。また、 経緯及び対応の記録を作成し保存すること。

- Q1-2 実施中の治験において、治験薬等を被験者宅に速やかに配送する必要があるため、事前に すべての実施医療機関と配送業者の間で、上記A1に示される医薬品GCP省令第39 条の2等の委受託契約を締結することが難しい場合、治験依頼者が遺定・契約する配送業 者により配送してもよいか。(実施医療機関・治験依頼者)
- A1-2 実施医療機関と治験依頼者で協議し、至急の対応を要する場合においては可能である。ただし、治験薬等の品質管理や被験者の個人情報等の取扱いを含めた業務内容を適切に取

## Tools for Early patient Access - Consultation Services -



## Supporting of COVID-19 Vaccines Development

Principles for the Evaluation of Vaccines Against the SARS-CoV-2 Sep 2020

 On 2nd Sep,2020 the PMDA published the "Principles for the Evaluation of Vaccines Against the Novel Coronavirus SARS-CoV-2", presenting basic principles concerning the efficacy and safety evaluation of COVID-19 vaccines in Japan.

## Free Scientific Advice for COVID-19 Vaccines Development

On 1st Oct,2020 the PMDA started to offer free of charge scientific advice meeting for the development of COVID-19 vaccines. In this meeting, vaccine companies and academic research organizations can discuss on overall development strategies including clinical trial protocols with PMDA reviewers of relevant offices, depending on the topics to be discussed.

## Actions against COVID-19

- Information of Approved Medical Products -

Medicines

**2** product approved

Active Ingredient	Brand Name	Applicant Company	Approval Date
Remesivir	VEKLURY for Intravenous Injection	Gilead Sciences K.K.	May 7, 2020*
Baricitinib	Olumiant Tablets 2mg/ Olumiant Tablets 4mg	Eli Lilly Japan K.K.	Apr 23, 2021

#### Vaccines

3 product approved

Active Ingredient	Brand Name	Applicant Company	Approval Date
Coronavirus Modified Uridine RNA Vaccine (SARS-CoV-2)	COMIRNATY intramuscular injection	Pfizer Japan Inc.	Feb 14, 2021*
Coronavirus Modified Uridine RNA Vaccine (SARS-CoV-2)	COVID-19 Vaccine Moderna Intramuscular Injection	Takeda Pharmaceutical Co., Ltd.	May 21, 2021*
COVID-19 Vaccine (SARS-CoV-2) Vaccine (recombinant chimpanzee adenovirus vector)	VAXZEVRIA Intramuscular injection	AstraZeneca K.K.	May 21, 2021*

#### **Medical Devices**

**16** product approved

JMDN	Brand Name	Applicant Company	Approval Date	JMDN	J	Brand Name	Applicant Company	Approv al Date
Ventilator for general purpose	NKV-550 Series Ventilator System	NIHON KOHDEN CORPORATION	Apr 24, 2020	Heart-lung I system	bypass	Heart Lung Machine S5	LivaNova Deutschland GmbH (designated MAH*:	Jul 13, 2020
Bi-level positive airway pressure unit	Philips Respironics E30 ventilator	Philips Japan, Ltd.	May 1, 2020	Multiparam monitor wit	:h	IntelliVue Patient	LivaNova(Japan)K.K.) Philips Japan, Ltd.	Jul 31, 2020
Adult ventilator	Philips Trilogy Evo Series	Philips Japan, Ltd.	May 12, 2020			Monitors MX750/850		
Software for diagnostic X-	COVID-19 Pulmonary image	CES Descartes Co., Ltd.	Jun 3, 2020	Ventilator fo	-	Evita V Series	Drager Japan, Ltd.	Sep 14, 2020
ray imaging system workstation	analyses Al program "InferRead CT			Neonatal/po c ventilator		Babylog VN Series	Drager Japan, Ltd.	Sep 14, 2020
workstation	Pneumonia"			Multiparam monitor wit		IntelliVue Patient	Philips Japan, Ltd.	Sep 17, 2020
Adult ventilator	Puritan Bennett 560	Covidien Japan, Inc.	Jun 12, 2020	critical para	meters	Monitors		
Adult ventilator	ACOMA Ventilator ART- 21EX	ACOMA Medical Industry Co., Ltd.	Jun 19, 2020	Software fo central mon with analyti capability	nitor	Philips information Center	Philips Japan, Ltd.	Nov 4, 2020
Heparin- coated aortic cannula	NSH heparin cannulae	SENKO MEDICAL INSTRUMENT Mfg. CO., Ltd.	Jun 25, 2020	Ventilator fo general pur		Puritan Bennett 980 series	Covidien Japan Inc.	Jan 8, 2021
Software for diagnostic X- ray imaging system	COVID-19 pneumonia image Analysis Program Ali-M3	MIC Medical Corp	Jun 29, 2020	Syringe with Needle for g purpose		TOP Syringe MV	TOP Corporation	Feb 10, 2021
workstation							As of May 25, 202	<sup>1</sup> 11

JMDN: Japanese Medical Device nomenclature

\*designated holder of marketing authorization for foreign-manufactured products

#### In Vitro Diagnostics

64 product approved

Approva I Date

Jun 19, 2020

Jul 2,

2020 Jul 31,

2020

Aug 11, 2020

Aug 17, 2020

Aug 18,

2020

Sep 8,

2020

Sep 8, 2020

Oct 13,

Oct 16, 2020

Oct 20,

2020

2020

Applicant

Company

Fujirebio Inc.

Denka Co., Ltd.

K.K.DNAFORM

Hologic Japan,

CORPORATION

**ARKRAY Factory**,

LABORATORIES,

Fujirebio Inc.

Diagnostics

Medical Co., Ltd.

SHIMADZU

Inc.

Inc.

INC.

TAUNS

Abbott

ТОУОВО

CO.,LTD.

Tosoh Corporation

						_
JMDN	Brand Name	Applicant Company	Approva I Date		JMDN	
SARS-CoV-2 nucleic acid kit	2019-nCoV Fluorescence	Sysmex Corporation	Mar 27, 2020	_	ARS-CoV-2 ntigen kit	
	Detection Real-time RT-PCR Kit*				ARS-CoV-2 ucleic acid kit	
SARS-CoV-2 nucleic acid kit	Loopamp Novel Coronavirus 2019(SARS-CoV-2)	Eiken Chemical Co., Ltd.	Mar 31, 2020	_	ARS-CoV-2 ucleic acid kit	
	Detection Kit*	Deska	A		ARS-CoV-2 ntigen kit	
SARS-CoV-2 nucleic acid kit	Cobas SARS-CoV-2*	Roche Diagnostic K.K.	Apr 7, 2020	S/	ARS-CoV-2	
SARS-CoV-2 nucleic acid kit	TaqPath Real Time PCR Reagent Kit for	Life Technologies	Apr 20, 2020		ucleic acid kit	
	SARS-Cov-2*	Japan Ltd.	2020	-	ucleic acid kit	
SARS-CoV-2 nucleic acid kit	Xpert Xpress SARS- CoV-2 'Cepheid'*	Beckman Coulter, Inc.	May 8, 2020	-	ARS-CoV-2 ucleic acid kit	
SARS-CoV-2 antigen kit	ESPLINE SARS-CoV- 2	Fujirebio Inc.	May 13, 2020	_	ARS-CoV-2 ucleic acid kit	
SARS-CoV-2 nucleic acid kit	MEBRIGHT SARS- CoV-2 Kit*	Medical & Biological Laboratories Co. Ltd.	May 21, 2020		ARS-CoV-2 ntigen kit	
SARS-CoV-2	FilmArray	bioMerieux	Jun 2,		ARS-CoV-2 ntigen kit	
nucleic acid kit/ Virus Nucleic Acid Isolation Kit/ Bacterial Nucleaic Acid Isolation Kit	Respiratory Panel 2.1	Japan Ltd.	2020	_	ARS-CoV-2 ucleic acid kit	

JMDN: Japanese Medical Device nomenclature

#### In Vitro Diagnostics (2)

JMDN	Brand Name	Applicant Company	Approval Date	JMDN	Brand Name	Applicant Company	Approva I Date
SARS-CoV-2 nucleic acid kit	GENECUBE HQ SARS-CoV-2	TOYOBO CO., Ltd.	2020 antigen kit F		Panbio COVID-19 Ag Rapid Test Device	Abbott Diagnostics Medical Co., Ltd.	Jan 22, 2021
SARS-CoV-2 nucleic acid kit / Influenza virus nucleic acid kit	SGNP nCoV/Flu PCR Detection Kit	SUDx-Biotec Corporation	Oct 23, 2020		(NASOPHARYNGEAL)/ Panbio TM COVID-19 Ag Rapid test Device (NASAL)		
SARS-CoV-2 nucleic acid kit	Takara SARS-CoV- 2 Direct PCR detection kit	Takara Bio Inc.	Oct 27, 2020	SARS-CoV-2 antigen kit	BD Veritor System for Rapid Detection of SARS- CoV-2	Becton, Dickinson and Company	Jan 26, 2021
Influenza Virus kit	Lumipluse Flu- A&B	Fujirebio Inc.	Nov 10, 2020	SARS-CoV-2 antigen kit	PRORAST SARS-CoV-2 Ag ADTest SARS-CoV-2	ADTEC Corporation/LSI medience	Jan 29, 2021
SARS-CoV-2 antigen kit	HISCL SARS-CoV-2 Ag Assay Kit	Sysmex Corporation	Nov 10, 2020			Corporation	
SARS-CoV-2	cobas SARS-CoV-2	Roche	Nov 13,	Influenza virus nucleic acid kit	Loopamp Influenza B virus Detection Kit	Eiken Chemical Co., Ltd.	Feb 2, 2021
nucleic acid kit / Influenza virus nucleic acid kit	& Flu A/B	Diagnostics K.K.	2020	SARS-CoV-2 antigen kit	SARS-CoV-2 Rapid Antigen Test	Rosch Diagnostics K.K.	Feb 9, 2021
Influenza virus kit	Lumipulse Presto Flu-A&B	Tujirebio Inc.	Dec 22, 2020	SARS-CoV-2 nucleic acid kit	Simprova SARS-CoV-2 Detection Kit	Eiken Chemical Co., Ltd.	Feb 15, 2021
Interferon-λ3 kit	HISCL IFN-λ3 Assay kit	Sysmex Corporation	Dec 22, 2020	SARS-CoV-2 nucleic acid kit	Takara SARS-CoV-2 & Flu Direct PCR detection kit	Takara Bio Inc.	Feb 15, 2021
SARS-CoV-2 nucleic acid kit	TRCReady SARS- CoV-2i	TOSOH CORPORATIO	Jan 19, 2021	SARS-CoV-2 antigen kit	FUJI DRI-CHEM IMMUNO AG HANDY COVID-19 Ag	FUJIFIRM Corporation	Feb 15, 2021
		N		Influenza virus nucleic acid kit	Simprova Influenza A virus Detection kit	Eiken Chemical Co., Ltd.	Feb 15, 2021
SARS-CoV-2 antigen kit	LuminaDx SARS- CoV-2 Ag Test Strip	LuminaDx Japan Co., Ltd.	Jan 19, 2021			May 25, 2021	13

### In Vitro Diagnostics (3)

JMDN	Brand Name	Applicant Company	Approva I Date	JMDN	Brand Name	Applicant Company	Approval Date
Influenza virus nucleic acid kit	Simprova Influenza B virus Detection kit	Eiken Chemical Co., Ltd.	Feb 15, 2021	Influenza Virus nucleic acid kit	Simprova Influenza A virus Detection kit	Eiken Chemical Co., Ltd.	Feb 15, 2021
SARS-CoV-2 antigen kit	Panbio COVID-19 Ag Rapid Test Device	Abbott Diagnostics	Jan 22, 2021	Influenza Virus nucleic acid kit	Simprova Influenza B virus Detection kit	Eiken Chemical Co., Ltd.	Feb 15, 2021
	(NASOPHARYNGEAL)/ Panbio TM COVID-19 Ag Rapid Test Device	Medical Co., Ltd.		SARS-CoV-2 nucleic acid kit	Smart Gene SARS-CoV- 2	MIZUHO MEDY Co., Ltd.	Feb 18, 2021
	(NASAL)			SARS-CoV-2	Sofia SARS Antigen FIA	Quidel	Feb 18,
SARS-CoV-2	BD Veritor System for	Becton,	Jan 26,	antigen kit		Corporation	2021
antigen kit	Rapid Detection of SARS-CoV-2	Dickinson and Company	2021	Influenza Virus kit	HISCL Influenza Assay Kit	Sysmex Corporation	Feb 18, 2021
SARS-CoV-2 antigen kit	PRORAST SARS-CoV-2 Ag ADTest SARS-CoV- 2	ADTEC Corporation/LS I Medience	Jan 29, 2021	SARS-CoV-2 nucleic acid kit	Alinity m system SARS- CoV-2	Abbott Japan LLC	Feb 24, 2021
		Corporation		SARS-CoV-2 antigen kit	Quick Chaser Auto SARS-CoV-2	MIZUHO MEDY Co., Ltd.	Mar 2, 2021
Influenza Virus nucleic acid kit	Loopamp Influenza B virus Detection kit	Eiken Chemical Co., Ltd.	Feb 2, 2021	SARS-CoV-2 antigen kit	FUJI DRI-CHEM IMMUNO AG CARTRIGE	MIZUHO MEDY Co., Ltd.	Mar 2, 2021
SARS-CoV-2 antigen kit	SARS-CoV-2 Rapid Antigen Test	Roche Diagnostics K.K.	Feb 9, 2021		COVID-19 Ag		
SARS-CoV-2 nucleic acid kit	Simprova SARS-CoV-2 Detection kit	Eiken Chemical Co., Ltd.	Feb 15, 2021	SARS-CoV-2 nucleic acid kit / Influenza Virus	Cobas Liat SARS-CoV-2 & Flu A/B	Roche Diagnostics K.K.	Mar 12, 2021
SARS-CoV-2	Takara SARS-CoV-2 &	Takara Bio Inc.	Feb 15,	nucleic acid kit			
nucleic acid kit	Flu Direct PCR detection kit		2021	SARS-CoV-2 antigen kit	ALSONIC COVID-19 Ag	Alfresa Pharma Corporation	Mar 12, 2021
SARS-CoV-2 antigen kit	FUJI DRI-CHEM IMMUNO AG HANDY COVID-19 Ag	FUJIFIRM Corporation	Feb 15, 2021		As of May 2	5, 2021	14

### In Vitro Diagnostics (4)

JMDN	Brand Name	Applicant Company	Approval Date
SARS-CoV-2 antigen kit	KBM Line Check nCoV (Stick Type)	KOHJIN BIO CO., LTD.	Mar 17, 2021
SARS-CoV-2 antigen kit	Elecsys SARS-CoV-2 Antigen	Roche Diagnostics K.K.	Mar 17, 2021
SARS-CoV-2 nucleic acid kit / Influenza virus nucleic acid kit	Xpert Xpress SARS-CoV- 2/Flu'Cepheid'	Beckman Coulter, Inc.	Apr 14, 2021
SARS-CoV-2 nucleic acid kit	DetectAmp SARS-CoV-2 RT-PCR Kit	Sysmex Corporation	Apr 14, 2021
SARS-CoV-2 antigen kit / Influenza Virus kit	COVID-19 and Influenza A+B Antigen Combo Test (NichireiBio)	Nichirei Biosciences Inc.	Apr 14, 2021
SARS-CoV-2 antigen kit	ImmunoArrow SARS- CoV-2	TOYOBO CO., LTD.	May 12, 2021
SARS-CoV-2 antigen kit	VITROS SARS-CoV-2 Antigen	ORTHO- CLINICAL DIAGNOSTICS K.K.	May 12, 2021

\* Due to the addition of specimen types to COVID-19 Manual by the National Institute of Infectious Diseases, partial change was approved on June 2 to add saliva as a specimen type to those already approved, e.g. specimen obtained from bronchoalveolar lavage and nasopharyngeal swabs.